Madam Chair, first of all, for Dylan and Kim, I appreciate the member's advocacy. I cannot imagine how difficult that circumstance is, and that is exactly what we want to shut down. This is precisely why we are acting on pharmacare.
One very important question we have is about which model to use. We have a pilot in P.E.I. that is working very well, which is based on a fill-in-the-gaps model. The model that Bill C-64 is based on is a universal model. We are now looking at those two models in a real-world setting to see which one is best to use as a delivery mechanism for all drugs. We have a committee that will be looking at that over the next year, which will really paint that path forward.
These are very active matters of consideration, and this is one of the reasons it is so important that we establish that bedrock, which is the legislative foundation for pharmacare in Bill C-64, and take this action. In this way, we can make sure that we get to help families such as that of Dylan and Kim. That is envisioned in Bill C-64, and very much in my heart and in my mind as we are working on this.